Connect with us


Here Are 3 Penny Stocks You Need to Know About in January

Which penny stocks are on your watchlist right now?
The post Here Are 3 Penny Stocks You Need to Know About in January appeared first on Penny Stocks to Buy, Picks, News and Information |



3 Penny Stocks to Add to Your January 2022 Watchlist 

As January 13th has become a volatile trading day for penny stocks and blue chips, many investors are looking for the best small-caps to buy. Now, it can be challenging to find penny stocks that are worth buying with so much going on in the stock market. 

However, because there are so many factors to consider, there is also a sizable amount of momentum to take advantage of. Right now, the main contributing factor to market volatility is the pandemic. And today, that resulted in a record jump in the price of wholesale goods as well as an unexpected climb in jobless claims. 

[Read More] 3 Top Penny Stocks To Watch As Redditors Buy The Dip

While 230,000 unemployment filings were made last week, this remains right around pre-pandemic levels. An economist at DWS Group, Christian Sherrmann, stated that “Persistent high inflation rates together with the recent strong labor market data reinforce the hawkish narrative provided by the Fed.” So, with all of this in mind let’s take a look at three penny stocks that could be worth watching this month.

3 Penny Stocks to Add to Your Watchlist in January 

  1. Rockwell Medical Inc. (NASDAQ: RMTI
  2. Vinco Ventures Inc. (NASDAQ: BBIG
  3. TDH Holdings Inc. (NASDAQ: PETZ

Rockwell Medical Inc. (NASDAQ: RMTI) 

One of the bigger gainers of the day so far is RMTI stock. By midday, shares of RMTI had pushed up by over 24% to almost $0.50 per share. While many penny stocks rise with no news behind it, Rockwell made a big announcement during premarket trading. Before we get into it, we have to take a look at what RMTI does. 

If you’re not familiar, Rockwell is a biopharmaceutical company working on the development of its next-gen parenteral iron technology platform known as Ferric Pyrophosphate Citrate of FPC. The company states that this platform has the potential to treat iron deficiency as a result of several diseases. Currently, Rockwell has two FDA-approved compounds for those going through hemodialysis. Today, the company announced regulatory approval of its Triferic compound in South Korea. With more than 82,000 patients going through hemodialysis in South Korea, this could be a substantial addressable market for the company. 

“The approval by MFDS is an important milestone for Rockwell Medical, but more importantly, for the more than 82,000 patients in South Korea undergoing hemodialysis. With its considerable development and commercialization capabilities and local market expertise, we believe Jeil is well-positioned to ensure that hemodialysis patients have access to our innovative therapeutic across South Korea.” 

The CEO of Rockwell Medical, Russell Ellison, M.D.

With this big news in mind, does RMTI deserve a spot on your list of penny stocks to watch or not?

Vinco Ventures Inc. (NASDAQ: BBIG) 

Vinco Ventures is a penny stock that we have covered numerous times in the past few months. And with a 13% gain today bringing its five-day gain to almost 40%, BBIG stock is once again seeing heightened popularity. Vinco Ventures is often referred to as a meme stock due to its consistent mentions on social media. 

While this could be one of the main reasons for its movement today, investors are also hopeful for its Lomotif app which is a competitor of TikTok. Currently, Vinco has an 80% stake in Lomotif, which was purchased through a joint venture between it and Zash Global Media and Entertainment. While Lomotif is nowhere near as large as TikTok, the potential market size given the popularity of online video-sharing apps right now is major. 

[Read More] Best Penny Stocks to Buy Today? 3 That Climbed in Premarket

The company states that the app has more than 31 million users per month that are active and on-platform. Additionally, the company is working to integrate Adrizer onto the platform which will hopefully bring in a greater chance of higher advertising revenue. While a lot is in the air for BBIG stock, there is also a lot to look forward to. Considering that, will BBIG be on your penny stocks watchlist?


TDH Holdings Inc. (NASDAQ: PETZ) 

Another decent gainer of the day so far is PETZ stock. By midday, shares of PETZ had climbed by around 5% to over $0.60 per share. This comes after a five-day drop of more than 84% with the bulk of that occurring earlier in this week. While today’s gain may be the result of a positive correction, it’s worth taking a look at what the company does. In its most recent announcement, PETZ put out its first half of 2021 financial results. 

In the results, the company posted a decrease in revenue of over 50% over the same period of the previous year. The company states that this was due to labor arbitration as well as the effects of the pandemic. With an operating loss of $1.17 million alongside a gross loss of $0.18 million, it’s clear that PETZ financial situation is nothing to write home about. 

If you’re not familiar, TDH Holdings is a producer of a large range of pet food products. These products are sold across China, Asia and Europe, which has allowed it to vastly broaden its reach. So, while PETZ stock has had a less than stellar year so far, it looks like we could be seeing a small bullish turnaround for the company right now. Whether this makes it worth buying or not is up to you. 


Which Penny Stocks Are You Buying in 2022?

With such a long list of penny stocks to buy, how can we pick the best ones for our portfolios? Well, the short answer is that it can be tricky. But, with a consistent understanding of what’s going on in the stock market and how to trade, it can be much easier than previously imagined. Right now, the main point of focus for all investors is the pandemic. 

[Read More] 3 Penny Stocks to Watch Under $1 Right Now

However, we also have to contend with external factors such as the U.S. economy, jobs reports, inflation, and so on. So, while investing right now is not for the faint of heart, it can be profitable if done correctly. With that in mind, which penny stocks are you buying in 2022?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post Here Are 3 Penny Stocks You Need to Know About in January appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


About 35% of People Who Received Placebo in Vaccine Trials Report Side Effects and More COVID-19 News

According to a recent study conducted by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center, 76 percent of the adverse side effects (such as fatigue or headache) that people experienced after receiving their first COVID-19…



About 35% of People Who Received Placebo in Vaccine Trials Report Side Effects and More COVID-19 News

The placebo effect is where a person who received a placebo instead of a drug or vaccine shows clinical signs, positive or negative, associated with the actual treatment. Much has been made about the side effects of the COVID-19 vaccines, but a new study found a startlingly high number of adverse events associated with people who received placebos in clinical trials. For that and more COVID-19 news, continue reading.

COVID-19 Vaccine Side Effects: Real or Placebo Effect?

A recent study out of Harvard Medical School and Beth Israel Deaconess Medical Center evaluated 12 COVID-19 vaccine trials with a total of 45,380 participants. The study found that 76% of the adverse side effects reported, such as fatigue or headache, after the first shot were also reported by participants who received a placebo. Mild side effects were more common in people receiving the vaccine, but a third of those given the placebo reported at least one adverse side effect. The statistics from the study showing that 35% of placebo recipients reported adverse side effects is considered unusually high. Several experts suspect that there’s such a high report of adverse events because of the amount of misinformation found on social media about the dangers of the vaccines and the amount of media coverage.

This is not to say that the adverse side effects felt by people who received the vaccines are all in their heads. People do have side effects to vaccines, but this study reports on an unusually high level of the placebo effect. Nocebo is used to describe a negative outcome associated with the placebo.

Source: BioSpace

“Negative information in the media may increase negative expectations towards the vaccines and may therefore enhance nocebo effects,” said Dr. Julia W. Haas, an investigator in the Program in Placebo Studies at Beth Israel Deaconess and the study’s lead author. “Anxiety and negative expectation can worsen the experience of side effects.”

Four Factors for Long COVID

A study published in Nature Communications identified specific antibodies in the blood of people who developed long COVID. Long COVID is not well understood and has a range of up to 50 different symptoms, and it is difficult to diagnose because there is no one test for it. The study, conducted by Dr. Onur Boyman, a researcher in the Department of Immunology at University Hospital Zurich, compared more than 500 COVID-19 patients and found several key differences in patients who went on to present with long COVID. The most obvious was a significant decrease in two immunoglobulins, IgM and IgG3. The study found that a decrease in these two immunoglobulins, which generally rise to fight infections, combined with other factors, such as middle age and a history of asthma, was 75% effective in predicting long COVID.

75% of COVID-19 ICU Survivors Show Symptoms a Year Later

A study out of the Netherlands found that a year after being released from an intensive care unit (ICU) for severe COVID-19, 75% of patients reported lingering physical symptoms, 26% reported mental symptoms, and up to 16% noted cognitive symptoms. The research was published in JAMA. The research evaluated 246 COVID-19 survivors treated in one of 11 ICUs in the Netherlands. The mental symptoms included anxiety (17.9%), depression (18.3%), PTSD (9.8%). The most common new physical symptoms were weakness (38.9%), stiff joints (26.3%), joint pain (25.5%), muscle weakness (24.8%), muscle pain (21.3%) and shortness of breath (20.8%).

Pennsylvania Averaging Most COVID-19 Deaths Per Day in a Year

In general, COVID-19 deaths are dropping across the country. However, in two states, Pennsylvania and New Jersey, the numbers are increasing. Pennsylvania is averaging 156 COVID-19 deaths per day over the past seven days, which is a 17% uptick compared to two weeks ago. The number of deaths per day in Pennsylvania is below what was hit in January 2021, largely due to the availability of vaccines. New Jersey averages 111 deaths from COVID-19 per day, an increase of 61% over the last two weeks and the highest since May 2020. Similarly, New Jersey cases and hospitalizations are declining.

Omicron Surge: Shattering Cases and Hospitalizations, but Less Severe

According to the CDC, although the current Omicron surge is setting records for positive infections and hospitalizations, it’s less severe than other waves by other metrics. Omicron has resulted in more than 1 million cases per day in the U.S. on several occasions, and reported deaths are presently higher than 15,000 per week. However, the ratio of emergency department visits and hospitalizations to case numbers is lower compared to COVID-19 waves for Delta and during the winter of 2020–21. ICU admissions, length of stay, and in-hospital deaths were all lower with Omicron. They cite vaccinations and booster shots as the likely cause. Although the overall result is that Omicron appears less severe, it’s not completely clear if that’s because the viral variant doesn’t infect the lower lung as easily as other variants, or because so much of the population has either been vaccinated or exposed to the virus already. It is clearly far more infectious than other strains, which is placing a real burden on healthcare systems. The number of emergency department visits is 86% higher than during the Delta surge.

J&J Expects Up to $3.5 Billion in COVID-19 Vaccine Sales This Year

Johnson & Johnson projected annual sales of its COVID-19 vaccine for 2022 to range from $3 billion to $3.5 billion. This was noted during the company’s fourth-quarter 2021 report. In December 2021, the U.S. Centers for Disease Control and Prevention recommended the PfizerBioNTech or Moderna shots over J&J’s due to a rare blood condition observed with the J&J shot. By comparison, Pfizer and BioNTech project their vaccine will bring in $29 billion in 2022, after having raked in almost $36 billion in 2021. Moderna expects approximately $18.5 billion this year, with about $3.5 billion from possible additional purchases. Although final figures for Moderna aren’t in yet, they projected 2021 sales between $15 and $18 billion.

BioSpace source:

Read More

Continue Reading


Oil Could Be The Haven Stocks Traders Need To Shelter From Fed

Oil Could Be The Haven Stocks Traders Need To Shelter From Fed

By Nour Al Ali, Bloomberg Markets Live commentator and analyst

Oil is starting to look like an unlikely haven from the stocks selloff in the run-up to anticipated Fed tightening.



Oil Could Be The Haven Stocks Traders Need To Shelter From Fed

By Nour Al Ali, Bloomberg Markets Live commentator and analyst

Oil is starting to look like an unlikely haven from the stocks selloff in the run-up to anticipated Fed tightening.

Traders are pricing lower volatility in the commodity than in the Nasdaq and S&P 500. Barometers of market anxiety for both indexes have shot up recently, suggesting trader sentiment is souring. Meanwhile, the CBOE Crude Oil Volatility Index, which measures the market’s expectation of 30-day volatility of crude oil prices applying the VIX methodology to USO options, shows that oil prices are expected to remain relatively muted in comparison.

With a producer cartel to support prices, the outlook for oil is more sanguine, even if the Fed raises rates. The commodity has ample support, with global oil demand expected to reach pre-pandemic levels by the end of this year. The U.S. administration has been pushing oil-producing nations under the OPEC+ cartel to ramp up output, while the group has stuck to a modest production-increase plan and is expected to rubber-stamp another 400k b/d output hike when they meet next week. This means that oil is likely to stay a lot more stable than in recent years.

The relatively low correlation between the asset classes provide diversification benefits. The relationship between the S&P 500 and the global oil benchmark is weak and lacks conviction; it’s even weaker between the Nasdaq 100 and Brent crude contracts. The divergence in price action this week could indicate that stocks have been tumbling in fear of a hawkish Feb, more so than geopolitical risk alone. That would perhaps offer traders an opportunity to seek shelter amid stock volatility in anticipation of the Fed’s next move.

Oil might have tracked the decline in stocks at the beginning of this week, but the commodity is back to its highs now. It’s up close to 15% this year, while the S&P 500 is struggling to reclaim its footing after plunging as much as 10%.

Tyler Durden Wed, 01/26/2022 - 13:45

Read More

Continue Reading


AT&T down 10% despite topping estimates

AT&T (NYSE: T) has revealed that Q4 results indicated continued users for the HBO MAX, wireless and fiber segments. In addition, the company gained more postpaid phone users for the whole year than the last ten years adding one million fiber subscribe



AT&T (NYSE: T) has revealed that Q4 results indicated continued users for the HBO MAX, wireless and fiber segments. In addition, the company gained more postpaid phone users for the whole year than the last ten years adding one million fiber subscribers. Similarly, the company beat its high-end outlook for international HBO Max and HBO users with almost 74 million subscribers as of December 31, 2021.

CEO John Stankey said:

We ended 2021 the way we started it – by growing our customer relationships, running our operations more effectively and efficiently, and sharpening our focus. Our momentum is strong and we’re confident there is more opportunity to continue to grow our customer base and drive costs from the business.

Q4 2021 revenue dropped 10% YoY

Consolidated revenue in Q4 2021 was $40.96 billion beating consensus estimates $40.68 but dropping 10% YoY, which reflects the impact of divested segments and low Business Wireline revenues. In the third quarter, the company divested US Videos, and in Q4, it divested Vrio. The drop was partially offset by high Warner Media revenues, recovery from pandemic impacts, and high Consumer Wireline and Mobility revenues. Stankey commented:

We’re at the dawn of a new age of connectivity. Our focus now is to be America’s best connectivity provider and also ensure our media assets are positioned to grow and truly become a global media distribution leader. Once we do this, we’ll unlock the true value of these businesses and provide a great opportunity for shareholders.

AT&T reported Q4 net income (loss) attributable to $5 billion or $0.69 per diluted shared share. On an adjusted basis, including merger-amortization fees, a share of DirecTV intangible amortization, gain on benefit plans, and related items, the company had an EPS of $0.78 topping consensus estimate of $0.76 per share.

AT&T had total revenue of $168.9 billion in 2021

AT&T’s consolidated revenues were $168.9 billion in 2021, compared to $171.8 billion a year ago, reflecting the split of the U.S Video division in Q3 2021, as well as the effects of other divested operations. However, higher revenues in WarnerMedia and Communications somewhat offset these declines.

For the full-year, net income (loss) attributable to commons shares was $19.9 billion or $2.76 p were per diluted share. On an adjusted basis, FY 2021 earnings per share were $3.4.

La notizia AT&T down 10% despite topping estimates era stato segnalata su Invezz.

Read More

Continue Reading